Quick Answer
KalVista Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $131.62 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed an increase of +314.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2012 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $9.28 million | Q2 2014: $7.18 million | Q3 2014: $9.33 million | Q4 2014: $3.90 million | Q1 2015: $3.18 million | Q2 2015: $65.38 million | Q3 2015: $59.88 million | Q4 2015: $53.72 million | Q1 2016: $24.17 million | Q1 2016: $48.46 million | Q2 2016: $36.82 million | Q3 2016: $15.63 million | Q3 2016: $35.21 million | Q4 2016: $10.69 million | Q1 2017: $33.50 million | Q3 2017: $26.46 million | Q4 2017: $28.13 million | Q1 2018: $58.68 million | Q2 2018: $51.06 million | Q3 2018: $48.07 million | Q4 2018: $121.12 million | Q1 2019: $56.35 million | Q3 2019: $30.11 million | Q4 2019: $21.72 million | Q1 2020: $18.62 million | Q3 2020: $18.01 million | Q4 2020: $16.17 million | Q1 2021: $17.73 million | Q3 2021: $48.34 million | Q4 2021: $46.49 million | Q1 2022: $45.58 million | Q3 2022: $37.86 million | Q4 2022: $38.59 million | Q1 2023: $85.05 million | Q3 2023: $49.41 million | Q4 2023: $57.67 million | Q1 2024: $23.06 million | Q3 2024: $31.85 million | Q4 2024: $41.58 million | Q4 2024: $182.33 million | Q1 2025: $167.29 million | Q2 2025: $131.62 million | Q3 2025: $124.30 million | Q3 2025: $243.50 million.
- Over the full 16 years of available data (2012 to 2025), KalVista Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,496.9%.
- Historical annual values: Fiscal year 2025: $131.62 million | Fiscal year 2024: $31.79 million | Fiscal year 2023: $56.24 million | Fiscal year 2022: $30.73 million | Fiscal year 2021: $50.59 million | Fiscal year 2020: $15.79 million | Fiscal year 2019: $32.01 million | Fiscal year 2018: $51.06 million | Fiscal year 2017: $30.95 million | Fiscal year 2016: $21.76 million | Fiscal year 2015: $53.72 million | Fiscal year 2015: $2.53 million | Fiscal year 2014: $3.90 million | Fiscal year 2014: $481.0 thousand | Fiscal year 2013: $9.78 million | Fiscal year 2012: $8.24 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: